Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
1.030
+0.030 (3.01%)
At close: May 16, 2025, 4:00 PM
1.000
-0.030 (-2.91%)
After-hours: May 16, 2025, 4:08 PM EDT
Akoya Biosciences Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Akoya Biosciences stock ranges from a low of $1.65 to a high of $5.00. The average analyst price target of $2.65 forecasts a 157.28% increase in the stock price over the next year.
Price Target: $2.65 (+157.28%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Akoya Biosciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $3.5 → $1.8 | Hold | Maintains | $3.5 → $1.8 | +74.76% | Apr 29, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $2.4 → $1.65 | Hold | Maintains | $2.4 → $1.65 | +60.19% | Apr 14, 2025 |
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades $3.5 → $1.8 | Buy → Hold | Downgrades | $3.5 → $1.8 | +74.76% | Mar 25, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $3.5 | Buy | Reiterates | $3.5 | +239.81% | Mar 18, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | +191.26% | Nov 19, 2024 |
Financial Forecast
Revenue This Year
92.54M
from 81.67M
Increased by 13.30%
Revenue Next Year
105.50M
from 92.54M
Increased by 14.01%
EPS This Year
-0.65
from -1.12
EPS Next Year
-0.50
from -0.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 99.2M | 118.6M | 134.7M | ||
| Avg | 92.5M | 105.5M | 113.1M | ||
| Low | 85.6M | 90.2M | 95.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.5% | 28.1% | 27.7% | ||
| Avg | 13.3% | 14.0% | 7.2% | ||
| Low | 4.8% | -2.6% | -9.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.46 | -0.36 | -0.48 | ||
| Avg | -0.65 | -0.50 | -0.50 | ||
| Low | -0.74 | -0.65 | -0.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.